NextPoint Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, raised $42.5M in Series B extension funding.
The round, which brought the total amount of Series B to $122.5M, was led by Catalio Capital Management. As part of the financing, R. Jacob Vogelstein, PhD, joined the NextPoint Board of Directors. Existing investors including MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD., and new investors Arkin Bio-Capital and WTT investment, also participated.
The company intends to use the funds to advance its two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen.
Led by CEO Ivan Cheung, NextPoint is advancing the field of immuno-oncology through its scientific work on the novel HHLA2 axis, also known as B7-H7. Its approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. The company is simultaneously advancing therapeutic approaches utilizing the upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Its team of drug developers is working closely with its scientific founders to launch new precision immuno-oncology treatments.
FinSMEs
15/02/2024